Medidata’s Intelligent Trials brings together cross-industry real-time performance metrics, predictive models, and forecasting capabilities to provide a competitive edge in trial planning and execution. “By providing our standardized and analysis-ready demographic and operational data in a study’s planning stages, sponsors and CROs can optimize planning and diversity performance from the start.” This supports more representative outcomes, and promotes much needed equity within clinical research,” said Fareed Melhem, senior vice president, Medidata AI. With this new offering, it is now possible to identify high-performing sites known to recruit diverse patients. “Powering greater diversity is critical for our industry and a priority for Medidata. New Medidata research* shows that in the past decade 70% of sites did not enroll a single Black participant in Alzheimer’s and lung cancer trials, two diseases that disproportionately affect Black Americans. Historically, clinical trials have been shown to recruit disproportionately white participants, which raises concerns about the generalizability of trial results to underrepresented patients. This insight will help bring diversity into the beginning of the feasibility process, all while accelerating trials.
The new Intelligent Trials Diversity Module will help sponsors and clinical research organizations (CROs) benchmark the diversity of their trials and identify sites that are more successful at enrolling diverse patients. NEW YORK-( BUSINESS WIRE)- Medidata, a Dassault Systèmes company, has launched the Intelligent Trials Diversity Module to help improve the equity of clinical trials by providing site-level participant demographic data including race, sex, age, and ethnicity.
0 kommentar(er)
